Treatment effect of switching from salmeterol/fluticasone to formoterol/budesonide combinations in patients with asthma

Treatment effect of switching from salmeterol/fluticasone to formoterol/budesonide combinations in patients with asthma - Comparison of salmeterol/fluticasone with formoterol/budesonide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009619

Enrollment

Registered

2012-12-25

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Switch from salmeterol/fluticasone (Adoair) 50/250 ug one inhalation twice daily to formoterol/budesonide (Symbicort) 4.5/160 ug two inhalation twice daily for 12 weeks Continue salmeterol/fluticasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Salmeterol/budesonide 50/250ug one inhalation twice daily at constant dose for more 2 months Ability and willingness to provide informed consent

Exclusion criteria

Exclusion criteria: History of hypersensitivity to budesonide and formoterol History or presence of lung, cardiac, renal and liver desease Use of systemic corticosteroids

Design outcomes

Primary

Measure	Time frame
CaNO at week 0 and week 12	—

Secondary

Measure	Time frame
J'awNO at week 0 and week 12 FeNO at week 0 and week 12 FEF75 at week 0 and week 12 FEF50 at week 0 and week 12 FVC at week 0 and week 12 Adverse events at week 0 and week 12 Mean rate of all exacerbations at week 0 and week 12	—

Countries

Japan

Contacts

Public ContactTaisuke Akamatsu

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026